Welcome to the e-CCO Library!

DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Rimola1, J.F. Colombel2, B. Bressler3, S. Adsul4, J. Siegelman5, P.E. Cole6, D. Lindner7, S. Danese8

Created: Thursday, 30 January 2020, 10:12 AM
DOP15: Clinical relevance of endoscopic peri-appendiceal red patch in Ulcerative Colitis patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Reijntjes, M.(1);Heuthorst, L.(1);Gecse, K.(2);Mookhoek, A.(3);Bemelman, W.(1);Buskens, C.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP15: Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during endoscopy
Year: 2022
Source: ECCO'22
Authors: Gabriëls, R.Y.(1);Linssen, M.(1);van der Waaij, A.(1);Volkmer, P.(1);Hooghiemstra, W.(1);Kats-Ugurlu, G.(2);Robinson, D.(3);Dijkstra, G.(1);Nagengast, W.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP15: Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn's disease: a multicentre prospective study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Morão, B.(1)*;Revés, J.(1);Nascimento, C.(1);Frias Gomes, C.(1);Cúrdia Gonçalves, T.(2);Freitas, M.(2);Castro, F.(2);Moreira, M.J.(2);Cotter, J.(2);Pereira, F.(3);Caldeira, A.(3);Sousa, R.(3);Coelho, R.(4);Macedo, G.(4);Macedo, C.(5);Ferreira, M.(5);Glória, L.(1);Torres, J.(1);Palmela, C.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP15: Metabolomics coupled with pathway analysis characterise metabolic changes in treatment-naive ulcerative colitis patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Diab*1, T. Hansen1, R. Goll2, E. Jensen1, T. Moritz3, J. Florholmen4, G. Forsdahl1

Created: Friday, 22 February 2019, 9:41 AM
DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Chen1, M. Rosario2, D. Polhamus3, N. Dirks3, W. Zhang4, W. Sun1, K. Kisfalvi5, B. Feagan6, W. Sandborn7, S. Vermeire8, G. D’Haens9

Created: Thursday, 30 January 2020, 10:12 AM
DOP16: Anti-integrin ⍺vβ6 autoantibodies predate Ulcerative Colitis diagnosis by up to 10 years and are associated with adverse disease-related outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Livanos, A.(1)*;Dunn, A.(2);Fischer, J.(2);Ungaro, R.C.(1);Turpin, W.(3);Lee, S.H.(3);Rui, S.(1);Del Valle, D.M.(2);Jougon, J.J.(4);Martinez-Delgado, G.(2);Riddle, M.S.(5);Murray, J.A.(6);Laird, R.M.(7);Torres, J.(8);Agrawal, M.(1);Magee, J.S.(9);Dervieux, T.(10);Gnjatic, S.(2);Sheppard, D.(11);Sands, B.E.(1);Porter, C.K.(7);Croitoru, K.(3);Petralia, F.(12);Colombel, J.F.(1);Mehandru, S.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP16: Categorizing endoscopic severity of Crohn’s Disease using the Modified Multiplier SES-CD (MM-SES-CD)
Year: 2022
Source: ECCO'22
Authors: Narula, N.(1);Pray, C.(1);Wong, E.(1);Colombel, J.F.(2);Marshall, J.(1);Daperno, M.(3);Reinisch, W.(4);Dulai, P.(5);
Created: Friday, 11 February 2022, 3:52 PM
DOP16: Endoplasmic reticulum stress in subepithelial myofibroblasts increases the TGF-β1 activity that regulates fibrosis in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Li*1, J. Kuemmerle1

Created: Friday, 22 February 2019, 9:41 AM
DOP16: The ratio of submucosa thickness to the total bowel wall thickness can be a sonographic parameter to estimate endoscopic remission in Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Miyoshi, J.(1);Ozaki, R.(1);Yonezawa, H.(1);Mori, H.(1);Kawamura, N.(1);Matsuura, M.(1);Hisamatsu, T.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP17 Identification of biomarkers and mechanistic insight for upadacitinib in ulcerative colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Vermeire1, H. Guay2, B. Verstockt3, J. Fann4, J. Cheng4, F. Hong4, W.J. Lee5, A. Lacerda6, W. Zhou6, S. Danese7

Created: Thursday, 30 January 2020, 10:12 AM
DOP17: AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of inflammatory bowel disease (IBD)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Wang*1, T. John2, L. Zhang1, L. Zhu1, Y. Xu1, K. Chen1, S. Han1, J. Li1, F. Wang1, C. Deceneux3,4, A. Behren3,4, Z. Yang1

Created: Friday, 22 February 2019, 9:41 AM
DOP17: Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort study
Year: 2022
Source: ECCO'22
Authors: Lenfant, M.(1,2);Verstockt, B.(1,2);Sabino, J.(1,2);Vermeire, S.(1,2);Ferrante, M.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
DOP17: HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Calafat Sard, M.(1,2)*;Súria, C.(3);Mesonero, F.(4);de Francisco, R.(5);Yagüe Caballero, C.(6);de la Peña, L.(7);Hernández-Camba, A.(8);Marcè, A.(9);Gallego, B.(10);Martín-Vicente, N.(11);Rivero, M.(12); Iborra, M.(13);Guerra, I.(14); Carrillo-Palau, M.(15);Madero, L.(16);Burgueño, B.(17); Montfort, D.(18);Torres, G.(19);Teller, M.(20);Ferrer Rosique, J.Á.(21);Vega Villaamil, P.(22);Roig, C.(23);Ponferrada, Á.(24); Betoré Glaría, E.(25);Zabana, Y.(2,26); P. Gisbert, J.(2,27);Alcaide, N.(28);Camps, B.(29);Legido, J.(30);González Vivo, M.(31);Bosca-Watts, M.M.(32);Pérez-Martínez, I.(5);Casas Deza, D.(6,33);Guardiola, J.(7);Arranz Hernández, L.(8); Navarro, M.(34);Gomollon, F.(2,10);Cañete, F.(1,2); Mañosa, M.(1,2);Domènech, E.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
DOP17: In high-risk Crohn’s Disease patients, anastomosis configuration types have similar rates of endoscopic recurrence
Year: 2021
Source: ECCO'21 Virtual
Authors: Bachour, S.(1);Shah, R.(1);Lyu, R.(2);Rieder, F.(1);Cohen, B.(1);Qazi, T.(1);Lashner, B.(1);Lipman, J.(3);Regueiro, M.(1);Lightner, A.(3);Holubar, S.(3);Click, B.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP18 Impact of adherence to anti-tumour necrosis factor therapy on clinical outcomes in Crohn’s disease: A nationwide population-based study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.J. Park1, H. Koo2, Y. Park1, S.J. Park1, T.I. Kim1, W.H. Kim1, J.H. Cheon1, E.H. Han2

Created: Thursday, 30 January 2020, 10:12 AM
DOP18: Advanced optical diagnosis technology for assessment of endoscopic and histological remission in Ulcerative Colitis: A systematic review and meta-analysis
Year: 2022
Source: ECCO'22
Authors: Nardone, O.M.(1);Snir , Y.(2,3);Hodson, J.(4);Cannatelli, R.(1);Labarile, N.(1);Siau, K.(1,5);Hassan, C.(6);Yanai, H.(2,3);Dotan, I.(2,3);Ghosh, S.(1,7,8,9);Iacucci, M.(1,8,9);
Created: Friday, 11 February 2022, 3:52 PM
DOP18: Brain structural correlates of fatigue in active and quiescent Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Thomann, A.(1)*;Schmitgen, M.(2);Szabo, K.(3);Ebert, M.(4);Reindl, W.(4);Wolf, C.(5);
Created: Friday, 14 July 2023, 10:43 AM
DOP18: OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Vossenkamper1, K. Foster2, K. Nevin2, G. Tannahill*2, S. Flint2, T. T. McDonald1

Created: Friday, 22 February 2019, 9:41 AM
DOP18: UCEIS is associated with PRO2, partial Mayo and SCCAI remission in UC: Final results from a prospective study
Year: 2021
Source: ECCO'21 Virtual
Authors: Golovics, P.(1);Gonczi, L.(2);Reinglas, J.(3);Verdon, C.(3);Pundir, S.(3);Afif, W.(3);Wild, G.(3);Bitton, A.(3);Bessissow, T.(3);Lakatos, P.L.(3)
Created: Wednesday, 2 June 2021, 4:12 PM